

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

VOLUNTARY ANNOUNCEMENT

The board of directors (the “**Board**”) of Tongfang Kontafarma Holdings Limited (the “**Company**”, together with the subsidiaries, the “**Group**”) is pleased to announce that 重慶康樂製藥有限公司 (Chongqing Kangle Pharmaceutical Co., Ltd.*), being an indirect non-wholly owned subsidiary of the Company, has obtained a Certificate of Good Manufacturing Practices in relation to API (Hydroxychloroquine Sulfate) (原料藥硫酸羥氯喹) (the “**GMP Certificate**”) issued by Chongqing Food and Drug Administration (重慶市食品藥品監督管理局) which is valid up to 6 March 2023.

With the grant of the GMP Certificate, the Group is accredited to manufacture and sell pharmaceutical products for curing rheumatoid arthritis (類風濕關節炎), juvenile chronic arthritis (青少年慢性關節炎), discoid and systemic lupus erythematosus (盤狀和系統性紅斑狼瘡), and skin lesions caused or aggravated by sunlight (由陽光引發或加劇的皮膚病變) (the “**Products**”) in the People’s Republic of China. The Board believes that such accreditation represents the recognition of the Group’s capability in pharmaceutical products production. The Board also believes that the planned manufacturing and sale of the Products, which will be the new type of products of the Group, will enhance the overall business performance, and will be beneficial to the development and growth of the pharmaceutical business of the Group as a whole.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 15 March 2018

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Huang Yu (Chairman), Mr. Jiang Chaowen (Chief Executive Officer) and Mr. Ng Qing Hai; and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.

* *For identification purposes only*